<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04165486</url>
  </required_header>
  <id_info>
    <org_study_id>262SP101</org_study_id>
    <secondary_id>2019-001105-24</secondary_id>
    <nct_id>NCT04165486</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB101 Administered to Adults With Multiple System Atrophy</brief_title>
  <acronym>HORIZON</acronym>
  <official_title>A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB101 Administered Intrathecally to Adults With Multiple System Atrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biogen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to evaluate the safety and tolerability of multiple doses of BIIB101
      administered via intrathecal (IT) injection to participants with multiple system atrophy
      (MSA).

      The secondary objective is to evaluate the pharmacokinetic (PK) profile of BIIB101.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 7, 2020</start_date>
  <completion_date type="Anticipated">July 13, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 13, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events (AEs)</measure>
    <time_frame>Baseline up to Day 253</time_frame>
    <description>An AE is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Serious Adverse Events (SAEs)</measure>
    <time_frame>Screening up to Day 253</time_frame>
    <description>An SAE is any untoward medical occurrence that at any dose results in death, places the participant at immediate risk of death, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, results in a congenital anomaly/birth defect, or is a medically important event.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-Time Curve From Time Zero to Time of Last Measurable Concentration</measure>
    <time_frame>Pre-dose and multiple timepoints up to 24 hours post-dose on Day 1; pre-dose and multiple timepoints up to 6 hours post-dose on 3 subsequent days; post-dose on 6 subsequent days over a 5 ½ month period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Concentration (Cmax)</measure>
    <time_frame>Pre-dose and multiple timepoints up to 24 hours post-dose on Day 1; pre-dose and multiple timepoints up to 6 hours post-dose on 3 subsequent days; post-dose on 6 subsequent days over a 5 ½ month period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Concentration (Tmax)</measure>
    <time_frame>Pre-dose and multiple timepoints up to 24 hours post-dose on Day 1; pre-dose and multiple timepoints up to 6 hours post-dose on Days 29, 57 and 85; post-dose on Days 8, 36, 64, 92, 113 and 169</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Concentration of BIIB101</measure>
    <time_frame>Pre-dose and multiple timepoints up to 24 hours post-dose on Day 1; pre-dose and multiple timepoints up to 6 hours post-dose on 3 subsequent days; post-dose on 6 subsequent days over a 5 ½ month period</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Multiple System Atrophy</condition>
  <arm_group>
    <arm_group_label>BIIB101 Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be administered BIIB101 low dose and matching placebo via intrathecal (IT) injection at regular intervals.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BIIB101 Medium Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be administered BIIB101 medium dose and matching placebo via IT injection at regular intervals.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BIIB101 High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be administered BIIB101 high dose and matching placebo via IT injection at regular intervals.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIIB101</intervention_name>
    <description>Administered as specified in the treatment arm.</description>
    <arm_group_label>BIIB101 High Dose</arm_group_label>
    <arm_group_label>BIIB101 Low Dose</arm_group_label>
    <arm_group_label>BIIB101 Medium Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered as specified in the treatment arm.</description>
    <arm_group_label>BIIB101 High Dose</arm_group_label>
    <arm_group_label>BIIB101 Low Dose</arm_group_label>
    <arm_group_label>BIIB101 Medium Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Screening single-photon emission computed tomography (SPECT) with DaTscan™ (ioflupane
             I123 injection) results demonstrating loss (whether symmetric or asymmetric) of
             dopamine nerve terminals in the striatum consistent with neurodegenerative
             parkinsonism, as assessed with qualitative, visual read.

          -  Diagnosed with probable or possible MSA, either parkinsonian-type (MSA-P) or
             cerebellar-type (MSA-C).

          -  Must be able to walk unassisted for at least 10 meters (approximately 30 feet)

        Key Exclusion Criteria:

          -  Presence of cognitive dysfunction (defined as Montreal Cognitive Assessment (MoCA)
             score &lt;25)

          -  Family history of ataxia or parkinsonism and known genetic cause of ataxia or
             parkinsonism.

        NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Biogen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US Biogen Clinical Trial Center</last_name>
    <phone>866-633-4636</phone>
    <email>clinicaltrials@biogen.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Global Biogen Clinical Trial Center</last_name>
    <email>clinicaltrials@biogen.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medizinische Universität Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Klaus Seppi</last_name>
      <phone>+4351250425810</phone>
      <email>lki.ne.parkinson@tirol-kliniken.at</email>
    </contact>
    <investigator>
      <last_name>Klaus Seppi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Purpan</name>
      <address>
        <city>Toulouse Cedex 09</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier Rascol</last_name>
      <phone>+33561779103</phone>
      <email>cic1436@inserm.fr</email>
    </contact>
    <contact_backup>
      <last_name>Stephanie Bras</last_name>
      <phone>+33561772474</phone>
      <email>stephanie.bras@inserm.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Olivier Rascol</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>France</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
    <country>Portugal</country>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 14, 2019</study_first_submitted>
  <study_first_submitted_qc>November 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2019</study_first_posted>
  <last_update_submitted>July 22, 2020</last_update_submitted>
  <last_update_submitted_qc>July 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple System Atrophy</mesh_term>
    <mesh_term>Shy-Drager Syndrome</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on http://clinicalresearch.biogen.com/</ipd_description>
    <ipd_url>http://www.biogenclinicaldatarequest.com/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

